Paid Clinical Trials Oklahoma
Discover 846 paid clinical trials in Oklahoma. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Sponsor:
Amgen
Location:
Code:
NCT06072482
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Avacopan
Placebo
Standard of Care
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome with Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable CancersTesting the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05803382
Conditions
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BET Bromodomain Inhibitor ZEN-3694
Biopsy
Biospecimen Collection
Capecitabine
Computed Tomography
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamideAndrogen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Sponsor:
Alliance Foundation Trials, LLC.
Location:
Code:
NCT04335682
Conditions
Metastatic Prostate Cancer
Prostate Cancer Metastatic
Prostate Cancer
Castrate Resistant Prostate Cancer
Hormone Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Darolutamide
Enzalutamide
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04164082
Conditions
Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Cystoscopy
Gemcitabine Hydrochloride
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Sponsor:
AbbVie
Location:
Code:
NCT05889182
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Placebo
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamA Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Sponsor:
Incyte Corporation
Location:
Code:
NCT06213831
Conditions
Prurigo Nodularis
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Ruxolitinib Cream 1.5%
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial HyperplasiaA Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT05903131
Conditions
Endometrial Hyperplasia
Grade 1 Endometrial Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Telemedicine behavioral weight intervention
Progestin
Enhanced usual care
Levonorgestrel-releasing IUD.
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor